The drug, designed by Pfizer, has loads of positives: It had an 89% reduction in the risk of hospitalization and Demise in unvaccinated individuals while in the scientific demo that supported the EUA, a number that was high sufficient to prompt the National Institutes of Wellness (NIH) to prioritize it around other COVID-19 treatments. Associate